Skip to main content
SSO 2024 Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded for On-Demand Viewing
Recorded for On-Demand Viewing
Back

UGI Great Debate: Should we use FLOT or CROSS for Neoadjuvant Therapy for Patients with Resectable Gastro-esophageal Junction Adenocarcinomas?

CROSS should be used as the Neoadjuvant Regimen for Patients with Resectable GEJ Adenocarcinomas

Saturday, March 23, 2024
10:00am – 10:15am ET
Location: C102

    Debater(s)

  • Yanghee Woo, MD

    Associate Professor
    Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA
    Duarte, California, United States

Disclosure(s):
Yanghee Woo, MD: Ethicon J&J: Consultant (Ongoing); Imugene: Advisor (Ongoing)
Patients with resectable gastroesophageal junction (GEJ) adenocarcinomas are often treated with neoadjuvant therapy. Treatment options include the FLOT chemotherapy regimen and the CROSS chemoradiation regimen. However, there are no guidelines on how to prioritize one over the other. How do we decide which regimen to use for patients with GEJ adenocarcinomas?